-

Savara to Host Analyst and Investor Webinar on September 30, 2024

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, will host an analyst and investor webinar on September 30, 2024 from 8:30-9:30 a.m. ET to present data from the Phase 3 IMPALA-2 clinical trial of molgramostim inhalation solution (molgramostim) in autoimmune Pulmonary Alveolar Proteinosis (aPAP) and provide updates on the global commercial landscape and the Company’s market development work.

The webinar will feature presentations from Savara's management team and the following key opinion leaders:

  • Ali Ataya, M.D., Associate Professor of Medicine, University of Florida, Division of Pulmonary and Critical Care Medicine
  • Bruce Trapnell, M.D., IMPALA-2 International Coordinating Investigator, Professor of Medicine and Pediatrics, University of Cincinnati College of Medicine

To access the webinar with slides please click here or visit the “Events & Presentations” section of Savara's website. To access the call by phone, please use this registration link and you will be provided with dial-in details. A replay of the webinar will be available approximately 24 hours after the conclusion of the call and archived for 90 days under the “Events & Presentations” section of the company's website at www.savarapharma.com.

About Savara

Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim inhalation solution, is a granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH). Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com. (X, formerly known as Twitter: @SavaraPharma, LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/).

Contacts

Savara Inc. IR & PR
Anne Erickson (anne.erickson@savarapharma.com)
(512) 851-1366

Industry:

Savara Inc.

NASDAQ:SVRA
Release Versions
English

Contacts

Savara Inc. IR & PR
Anne Erickson (anne.erickson@savarapharma.com)
(512) 851-1366

More News From Savara Inc.

Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced today that it has resubmitted the MOLBREEVI BLA to the FDA, with Fujifilm as the drug substance manufacturer. The MOLBREEVI BLA submission is seeking approval for the treatment of autoimmune PAP, a chronic and debilitating rare lung disease characterized by the abnormal build-up of surfactant in the alveoli. The Company has request...

Savara Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the “Company”), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the management team will present and host one on one meetings at the 44th Annual J.P. Morgan Healthcare Conference. Date/Time of Presentation: Wednesday, January 14, 5:15pm PT/8:15pm ET Presenter: Matt Pauls, Chair and Chief Executive Officer, Savara Location: Westin St. Francis, San Francisco, Elizabethan B...

Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI*

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the EPO notified the Company of its intention to grant a patent application covering the liquid formulation of MOLBREEVI, an orally inhaled recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). “The liquid formulation and drug-device patents will provide protection in Europe through March 2041 and March...
Back to Newsroom